ProCE Banner Activity

CE

Class in Session: Today’s Concepts on Targeted and CAR T-Cell Therapies Across B-Cell Malignancies

Watch this on-demand Webcast of a CCO symposium developed for pharmacists to gain expert perspectives on key considerations with targeted agents and CAR T-cell therapies in the evolving treatment landscape for B-cell malignancies.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: April 30, 2020

Expiration: April 29, 2021

No longer available for credit.

Share

Faculty

Zahra Mahmoudjafari

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Anthony Perissinotti

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with B-cell malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider efficacy and safety profile of the novel classes of therapies (including BTK and PI3K inhibitors, antibodies, BCL-2 inhibitors, CAR T-cell, investigational agents, and immunotherapeutic strategies currently under evaluation) with patient characteristics and molecular features to individualize therapeutic strategies for patients with mature B-cell lymphomas
  • Consider mechanisms of action and efficacy and safety profile differences among different agents in the same class of therapy to select treatments most likely to improve outcomes
  • Assess challenging questions regarding the use of novel therapies in mature B-cell lymphomas and discuss the ways that pharmacists can optimize therapy, anticipate adverse events, and optimize clinical outcomes alongside other members of the oncology healthcare team
  • Manage unique adverse events associated with novel agent classes in the management of mature B-cell lymphomas to optimize care and quality of life
  • Identify patients suitable for enrollment on ongoing clinical studies investigating novel therapies in mature B-cell lymphomas

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has disclosed that she has received consulting fees from Genentech, Incyte, Legend, and Omeros.

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP, has disclosed that he has received consulting fees from Amgen, Astellas, Celgene/Juno, Coherus, and Servier.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-053-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2020, through April 29, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate novel therapies (including BTK and PI3K inhibitors, next-generation antibodies, BCL-2 inhibitors, CAR T-cell, investigational agents, and immunotherapeutic strategies currently under evaluation) and recent findings into the treatment of patients with mature B-cell NHLs.